Scientists have now confirmed the length of protection for Pfizer's COVID-19 vaccine.
During Pfizer's Phase 3 clinical trial, researchers have found that protection lasts up to six months after the second dose.
Up until now, scientists estimated about 90 days of protection for all vaccines.
“These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,” Albert Bourla, Chairman and Chief Executive Officer, Pfizer said in a statement.
The Pfizer vaccine also remains more than 91% effective against variants of the virus, including the South African strain, that's been rapidly evolving.
“It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up,” said Ugur Sahin, CEO and Co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population.”